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An immediate-early protein of murine cytomegalovirus (MCMV), pp89, elicits an immunodominant and
protective major histocompatibility complex (MHC) class I Ld-restricted CD8+ T-lymphocyte response.
Remarkably, presentation of the naturally processed peptide of pp89, the nonapeptide YPHFMPTNL, is
abolished during permissive MCMV infection in vitro. This defect in pp89 presentation is due to the expression
ofMCMV early gene functions that specifically block the transport of peptide-charged MHC class I complexes
to the cell surface (M. Del Val, H. Hengel, H. Hacker, U. Hartlaub, T. Ruppert, P. Lucin, and U. H.
Koszinowski, J. Exp. Med. 176:729-738, 1992). Here, we demonstrate that MCMV-specific CD8+ T lympho-
cytes can reconstitute pp89 presentation in a parakrine fashion. The lymphocytes mediate the restoration of
antigen presentation by MCMV-infected cells by releasing gamma interferon (IFN--y). IFN--y has no effect on
synthesis and stability of the viral antigen pp89 nor does it interfere with the expression of viral early genes
and their inhibitory effect on MHC class I molecule maturation. IFN--y results in a 25-fold increase in the
synthesis of MHC class I molecules and a similar increase in the abundance of pp89-derived peptide. Many of
the MHC molecules remain retained by the viral effect, but a surplus ofMHC molecules escapes the effect and
provides the effective surface presentation of the peptide. Adoptive cell transfer studies demonstrate the IFN-'y
dependence of CD8+ T-lymphocyte function in vivo. Altogether, these data reconcile the paradoxical findings
of an impaired pp89 presentation in vitro in parallel with pp89-specific CD8+ T-cell protection in vivo. The
results also imply a role of IFN-y in the T-lymphocyte-mediated control of cytomegalovirus infection. The
known propensity of cytomegalovirus to cause serious disease in the immunocompromised host is discussed in
the light of these findings.
Major histocompatibility complex (MHC) class I molecules
bind peptides derived from endogenously synthesized proteins
and present them at the cell surface to CD8+ T lymphocytes.
Processing of antigens involves protein degradation and trans-
port to the endoplasmic reticulum for MHC binding. After
infection with a virus, cells degrade viral proteins in the cytosol
into short peptides of 8 to 11 amino acids in length (38, 42).
For antigen processing in the cytosol, a nonlysosomal protein-
ase complex that contains MHC-encoded subunits is regarded
as a candidate (18, 27, 29). The translocation of peptides into
the rough endoplasmic reticulum requires ATP-dependent
peptide transporter proteins of the ABC family (31, 41) or
occurs independently of ATP (23). Binding of antigenic pep-
tides to MHC class I heavy chains induces folding (43) and
stable association with ,B2m (22, 43) in the trimolecular MHC
class I complex that is transported to the plasma membrane.
MHC class I molecules lacking peptide have a different
conformation and are deficient with respect to surface trans-
port and stability (15, 25).
Cytomegalovirus (CMV) is a member of the herpesvirus
family and establishes acute and chronic infections. After
primary infection, CMV persists in the host for life in a latent
state from which reactivation can occur. While infection of the
immunocompetent host is usually asymptomatic, CMV causes
severe and fatal disease in immunocompromised individuals
(11, 14). MHC class I-restricted T lymphocytes play a crucial
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role in the host defense against CMV (21). This has been
experimentally demonstrated in several studies, e.g., in a
murine adoptive-transfer model in which specifically sensitized
CD8+ T lymphocytes limit viral spread, prevent tissue destruc-
tion, and protect against lethal murine cytomegalovirus
(MCMV) disease (33, 36). Vaccination with a recombinant
vaccinia virus expressing the nonstructural immediate early
(IE) protein pp89 of MCMV conferred protection against
lethal infection in BALB/c (H-2d) mice by the induction of
CD8+ T lymphocytes (16).
CMV gene expression is regulated in a cascade fashion
characteristic of herpesviruses and can be subdivided into an
IE, an early (E), and a late phase. Previous studies of MCMV
have demonstrated that CMV interferes with MHC class
I-dependent antigen presentation (8). Further analysis re-
vealed that E gene functions prevent the presentation of
peptides derived from IE-expressed proteins by blocking the
transport of the peptide-loaded MHC class I molecule Ld
through the Golgi compartment (7).
In this study, we set out to explain the apparent contradic-
tion between the generation of the dominant and protective
fraction of pp89-specific cytotoxic T lymphocytes (CTL) in vivo
and the control of the virus over antigen presentation in vitro.
We tested the recognition of MCMV-infected cells throughout
all three phases of infection. Here, we report that cytokines
produced by MCMV-specific CD8+ T cells compensate the
negative viral effect on antigen presentation. The major factor
could be identified as gamma interferon (IFN--y). Although
this cytokine also has direct antiviral activities, the effect upon
antigen presentation function is associated with the induction
of MHC class I genes of the host.
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MATERIALS AND METHODS
Mice. BALB/cJ (H-2") and B10.G (H-2") mice were kept in
our own colony under specific pathogen-free conditions.
Cells. Mouse embryo fibroblasts (MEF) prepared from both
strains of mice were used after three in vitro passages for virus
infections and extraction of naturally processed peptides.
Viruses. MCMV of the strain Smith (ATCC VR-194) was
used as tissue culture-grown virus. The recombinant MCMV
lacl, expressing the lacZ gene encoding P3-galactosidase as an
IE gene, has been described before (7).
Reagents and antibodies. Recombinant murine IFN-y was
kindly provided by G. R. Adolf, Bender Vienna, Vienna,
Austria. The specific activity of recombinant IFN-y (rIFN-y)
(lot M3-RD48) was 107 U/mg, as determined by the encepha-
lomyocarditis virus bioassay on L cells. The following mono-
clonal antibodies (MAbs) were used: 28-14-8S (anti-Ld03)
(ATCC HB 27), 64-3-7 (anti-Ldox2, selective for Ldalt) (24),
30-5-7 (anti-Ldox2, selective for ,B2m-associated Ld) (24), 34-
5-8S (anti-Dc') (ATCC HB 102), GK1.5 (anti-CD4) (ATCC
TIB 207), YTS-169.4 (anti-CD8) (6), YTS-191.1 (anti-CD4+)
(6), R4-6A2 (anti-murine IFN-y) (ATCC HB 170), AN-18
(anti-murine IFN-y) (32); and Vlq (anti-murine tumor necro-
sis factor) (12). Anti-MCMV serum was collected from latently
infected BALB/c mice. The peptide antiserum b5/1 has been
described previously (10). Rabbit anti-murine IFN-r antibod-
ies were purchased from Paesel and Lorei (Frankfurt/Main,
Germany), and purified rat immunoglobulin G was from
Dianova (Hamburg, Germany). Low Tox rabbit complement
was from Cedarlane Laboratories (Hornby, Ontario, Canada).
Infection conditions. Restriction of MCMV gene expression
to the IE phase was achieved by infecting cells in the presence
of cycloheximide (CH) (50 ,ug/ml), which was replaced 3 h later
by actinomycin D (actD) (5 [Lg/ml). Conditions of controlled
early gene expression were achieved by infection of cells in the
presence of CH for 3 h before CH was washed out and actD
was added after a 90-min period free of metabolic inhibitors.
IE proteins translated in this period activate the transcription
of E genes until actD blocks further transcription. In some
experiments, actD was added at the indicated time point after
infection to prevent further viral gene expression. Late-phase
gene expression was prevented by the use of phosphonoacetic
acid (250 plg/ml), which arrests MCMV-infected cells in the E
phase. In all experiments, cells were infected with a multiplicity
of infection of 0.3, and the infection was performed by
centrifugation at 800 x g for 30 min, in order to enhance the
efficiency by a factor of 20.
Isolation ofendogenously processed peptides. After trypsiniza-
tion, washing, and counting of cells, peptides were extracted
with trifluoroacetic acid from whole cell lysates (-4 x 107
cells) and separated first by size on a Sephadex G-25 column
and subsequently on a reverse-phase high-pressure liquid
chromatography (HPLC) column. Collected fractions were
lyophilized and tested after resuspension in medium with
pp89-specific CTL in a standard 'Cr-release assay as de-
scribed previously (7, 9).
Cytolytic assays. Target cells were trypsinized and labeled
for 90 min with Na25'CrO4, and a standard 4-h cytolytic assay
was performed with 103 target cells and graded numbers of
effector cells in fivefold dilution steps. Data represent the
mean percentage of specific lysis from three replicate cultures.
HPLC fractions to be tested were lyophilized and resolved in
culture medium before labelled P815 cells were incubated for
1 h at 37°C and cytolytic effector cells were added.
ELISA for determination of IFN-y. IFN-,y was detected in
a standard sandwich enzyme-linked immunosorbent assay
(ELISA) with the help of the anti-murine IFN-y-specific MAb
R4-6A2 as a capture antibody in conjunction with biotinylated
AN-18 MAb (32). Optical density values were measured in
duplicates and converted to units per milliliter according to a
standard curve obtained with recombinant murine IFN-y.
Metabolic labeling, immunoprecipitation, and endoglycosi-
dase H treatment. Cells were labeled with [35S]methionine
(1,200 Ci/mmol; Amersham, Braunschweig, Germany) at a
concentration of 500 pLCi/ml as described previously (7). In
brief, quantitative precipitations were performed sequentially
with ascitic fluids of the MAb 64-3-7, followed by 28-14-8S and
34-5-8S. To assure quantitative retrieval of immune complexes,
the lysates were incubated two more times with protein
A-Sepharose (Pharmacia, Freiburg, Germany) before addition
of the next MAb. Immune complexes were mock treated or
digested with 2 mU of endoglycosidase H (Endo H) (Boehr-
inger, Mannheim, Germany) overnight at 37°C, eluted with
sample buffer, and analyzed by 10 to 15% polyacrylamide
gradient gel electrophoresis. The gels were treated with
En3Hance (NEN-Dupont, Boston, Mass.), dried, and exposed
to X-Omat AR films at - 70°C for 1 to 7 days.
Adoptive transfer experiments. In vivo depletion of CD4+ T
lymphocytes in thymectomized donor mice was carried out as
described elsewhere (26, 36). In brief, depletion was started by
intravenous treatment with anti-CD4 MAb at a dose of I mg
for 3 successive days. A single antibody injection was repeated
every 7 days. For short-term depletion of CD8+ T lymphocytes
in adoptive transfer recipients, mice were injected intraperito-
neally with 1 mg of anti-CD8 MAb every 4th day, starting 1 h
after infection and cell transfer. In vivo neutralization of IFN--y
was achieved by the injection of 1 mg of R4-6A2 MAb for 2
successive days starting from the day of infection. Thereafter,
injections of 1 mg of R4-6A2 were repeated every 3rd day (26).
The prophylactic adoptive cell transfer was performed as
described elsewhere (36). Recipient mice were immunode-
pleted by total-body gamma-irradiation of 6 Gy delivered as a
single dose. At 2 h after irradiation and infection with 2 x 105
PFU of MCMV, 2 x 105 spleen lymphocytes from donor mice
were infused into the tail vein. Experiments were terminated 2
weeks after cell transfer, and virus titers in tissues of recipients
were determined.
RESULTS
Absence of antigen presentation of pp89 during the MCMV
replication in vitro. Selective and enhanced expression of
MCMV IE genes results in the presentation of the peptide
YPHFMPTNL derived from MCMV IE protein pp89 by the
MHC class I molecule Ld (8, 9) (Fig. IF). However, a 90-min
period of viral E gene expression suffices to prevent antigen
presentation of pp89, as shown before (8) and demonstrated in
Fig. 1G. In order to define the stages of pp89 presentation
during permissive MCMV infection, infected target cells were
tested with peptide-specific CTL throughout the MCMV rep-
lication cycle. As expected, the natural course of MCMV
infection was associated with inhibited pp89 presentation at
times of E gene expression 6 or 16 h postinfection. (Fig. IC and
D). However, in agreement with previous experiments (8) that
indicated at best marginal antigen presentation very early or
very late, pp89 peptides were not detectable within the first 90
min of infection (see Fig. 1 B) nor after 24 h of infection
representing the late phase of infection (Fig. lE). The virtual
absence of pp89 presentation was also observed during the
course of permissive infection when investigated in another
H-2 haplotype, H-2" (data not shown). At the same time as
when antigen presentation of pp89 was abolished, other
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FIG. 1. Absence of pp89 presentation during permissive MCMV infection. Presentation of pp89 peptides was tested by pp89-specific BALB/c
CTL (triangles) on MEF cells infected with MCMV for the indicated times before actD was added (A to E) to prevent further viral gene
expression. Subsequently, cells were harvested and labelled for 90 min with 51Cr before being assayed in a 4-h standard chromium release assay
with graded numbers of effector cells. In parallel, targets were incubated with MCMV-polyspecific BALB/c CTL (circles). Infection was performed
in the presence of CH, which was replaced after 3 h by actD to achieve enhanced and selective IE protein synthesis (F). Infection was performed
in the presence of CH, which was washed out after 3 h, allowing IE protein synthesis, followed by subsequent E gene transcription and translation.
The transcription of viral genes was terminated after 90 min by the addition of actD (G). E/T, effector-to-target cell ratio.
MCMV antigens that are not defined in molecular terms
escaped the E gene effect and could be detected by polyspecific
CTL during the later phases of infection at 16 and 24 h
postinfection (Fig. 1D and E) (8, 34). Recognition of pp89 in
cells arrested for selective IE gene expression due to abortive
infection could perhaps explain the generation of pp89-specific
CTL in vivo. However, this does not explain the established
capacity of pp89-specific CTL to control productive infection
in vivo (36). We therefore concluded that the lack of presen-
tation in vitro cannot reflect the conditions that govern pp89
presentation in vivo.
CD8+ T-cell-derived IFN--y restores pp89 presentation.
pp89-specific CTL dominate among polyspecific MCMV-spe-
cific T cells in vivo (35) as well as in vitro after restimulation of
primed splenocytes with MCMV (unpublished observation).
From these observations, we hypothesized that a regulatory
mechanism that compensates the inhibitory E gene effect and
provides pp89 recognition must exist. We reasoned that lym-
phocytes or monocytes in infected tissues could contribute to
antigen presentation by factor release. In search of such
factors, target cells were incubated with conditioned medium
derived from MCMV-specific T-cell cultures prior to infection
with MCMV. Remarkably, target cells treated that way now
presented pp89 antigen during the E phase of virus replication
(Fig. 2, right panel) to an extent comparable with that of cells
infected under IE conditions (Fig. 2, left panel). The same was
true for the presentation of another antigen, ,B-galactosidase,
when expressed as an IE gene from the recombinant MCMV
lacl (7) (data not shown). In order to identify the soluble
factor(s) responsible for the compensation of the viral effect,
neutralizing antibodies for several cytokines were used. The
MAb R4-6A2 neutralizing IFN-y abrogated the capacity of the
T-cell-conditioned supernatant to restore pp89 recognition by
CTL (Fig. 2, right panel). This identified IFN-y as an impor-
tant factor or cofactor for pp89 antigen presentation during
permissive infection.
Previous in vivo studies have revealed that the CD8+ T-cell
subset is able to control MCMV infection autonomously (17,
33). To determine the capacity of CD8+ T cells to produce
IFN-y in vitro, lymphocytes generated in MCMV-specific
T-cell cultures were harvested, depleted of either the CD4+ or
the CD8+ T-cell subset, and incubated with MCMV-infected
fibroblasts for 6 h before the IFN-y content in the supernatants
was measured in a sandwich ELISA. As detailed in Table 1, up
to 85 U of IFN-y per ml were produced within 6 h and
depletion of CD8+ T cells abrogated the production of IFN-y,
whereas the removal of CD4+ T cells had no effect. These data
identified MCMV-antigen-specific CD8+ T cells as a major
source of IFN--y under the experimental conditions chosen.
Kinetics of the restored pp89 presentation function by
rIFN--y. We tested whether IFN-y could mediate the effect on
its own or whether the synergistic action required further
cytokines in the T-cell-conditioned supernatant. As depicted in
Fig. 3, preincubation with recombinant IFN-y resulted in pp89
antigen presentation in a dose-dependent manner. In compar-
ison with MCMV-infected cells restricted to IE gene expres-
sion, 20 U of rIFN-y per ml fully compensated the MCMV E
gene effect and even at 0.2 U/ml showed a marginal effect. The
same results were obtained when pp89 peptides were pre-
sented by another class I molecule, Lq (data not shown). In
cells arrested for IE expression, antigen presentation was only
slightly improved by IFN-y. Studies on the kinetics of the
IFN-y effect revealed that for the restoration of antigen
presentation a preincubation of cells for 12 h was the minimum
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FIG. 2. Restoration of pp89 presentation by supernatant from
MCMV-specific T-cell cultures. At 48 h before MCMV infection,
conditioned medium (CM) from MCMV-polyspecific T-cell cultures
propagated for 4 weeks was transferred on MEF together with
anti-IFN-y MAb R4-6A2 (R4.6A2) or with polyclonal rabbit anti-
mouse IFN-,B or without antibodies. Target cells were infected as
described in Materials and Methods. Presentation of pp89 peptides
was determined in a chromium release assay using graded numbers of
pp89-specific CTL. IE, restriction of MCMV gene expression to the IE
phase; IE + E, conditions of controlled early genc expression. E/T,
effector-to-target cell ratio.
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TABLE 1. IFN-y production by MCMV-specific T lymphocytes"
IFN-y production' with indicated treatment of
Infection condition T lymphocytes
of target cells" Anti-CD8 + Anti-CD4 +
None complement complement
Mock 2 0.5 1.8
IE 85 2.5 65
E"d80 8 80
Late 70 4 80
T lymphocyte cultures (7.5 x 106 cells) from MCMV-primed BALB/c mice
were restimulated weekly with MCMV in vitro and allowed to rest for 3 weeks.
Before being measured for IFN-y production, harvested cells were washed and
at 5 x 105 cells per well were treated with either purified anti-CD8 MAb
YTS-169.4 plus complement or anti-CD4 MAb GK1.5 plus complement before
being incubated with 105 MCMV-infected or mock-infected MEF in 0.25 ml of
medium. After 6 h, 0.15 ml of the supernatant was removed and IFN-y was
determined by a sandwich ELISA.
h BALB/c MEF were infected with MCMV as described in Materials and
Methods.
' In units per milliliter.
d Phosphonoacetic acid was used to arrest gene expression in the E phase.
and 48 h of pretreatment represented the optimum (Fig. 4).
Two conclusions were drawn: first, that IFN-y alone is able to
mediate the effect; and second, that IFN-'y cannot restore
antigen presentation in already-infected cells.
IFN-y does not inhibit viral E gene expression. IFN-y
displays multiple effects on viral as well as cellular genes (30,
44). To find out whether IFN--y acts on antigen presentation by
affecting either viral E or cellular genes or both, the synthesis
of E proteins in IFN-y-conditioned cells was tested. The
MCMV E-phase factor responsible for the intracellular reten-
tion of correctly assembled MHC class I complexes (7) is not
yet identified. As markers, a set of viral E proteins was
precipitated with MCMV antiserum from E-phase-infected
cells pretreated with IFN-y or not and analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). As demonstrated in Fig. 5, the precipitated proteins
included the 36- and 38-kDa El proteins encoded by the
transcription unit el (4). el is under control of the same IE
genes and is transcribed simultaneously with the E gene(s) that
prevent pp89 presentation (unpublished observation). The
pattern of polypeptides induced after IFN-,y incubation re-
vealed no principal differences, although subtle alterations in
protein synthesis and stability of the El polypeptides were
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FIG. 4. For antigen presentation, IFN--y treatment of cells must
precede MCMV infection. Presentation of pp89 antigen was deter-
mined after different incubation periods with 20 U of IFN--y per ml
prior to infection of cells with MCMV under conditions permissive for
E gene expression (middle panel). Untreated target cells expressing IE
plus E or, selectively, IE genes were used as controls (left and right
panels, respectively). E/T, effector-to-target cell ratio.
noted (Fig. 5). A potential effect on pp89 synthesis or stability
was excluded from pulse-chase experiments (data not shown).
Effect of IFN-y on peptide processing. During permissive
MCMV infection, processing of pp89 to peptide is unabated
but presentation is prevented (7). We studied whether the
amount of processed antigenic peptides is altered with respect
to peptide quality and quantity in IFN-y-treated E-phase-
expressing cells. The analysis of endogenous pp89 peptides
after acidic extraction and reverse-phase HPLC separation
revealed no qualitative differences upon IFN-,y pretreatment
(Fig. 6A). Consistently, the biological activity was contained in
two antigenic peaks in fractions 25 and 27-28 of our HPLC
separation. Fraction 27-28 represents the nonamer peptide
IE MOCK IE+ E
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Chase(min) 180 180 0 180
0d- 71Sw
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FIG. 3. rIFN-y restores pp89 presentation dose dependently. Tar-
get cells were incubated with different doses of rIFN--y for 48 h. After
infection and expression of MCMV E genes, presentation of pp89 was
tested in a cytolytic assay using graded numbers of pp89-specific CTL.
Phosphonoacetic acid (PAA; 250 jig/ml, right panel) prevents late-
phase gene expression, thereby arresting MCMV-infected cells in the
E phase. IE and IE + E are defined as for Fig. 2. E/T, effector-to-target
cell ratio.
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tw-
- pp89
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FIG. 5. IFN-y does not inhibit viral E gene expression. Synthesis
and stability of viral proteins in IFN--y-pretreated cells were deter-
mined by metabolic labelling of infected cells with [35S]methionine for
90 min starting 3 h postinfection and chasing for the time indicated,
followed by immunoprecipitation of cell lysates with anti-MCMV
serum and analysis by SDS-PAGE. The positions of the IE1 protein
pp89 and the El proteins of 36 and 38 kDa are indicated. IE and IE +
E are defined as for Fig. 2.
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FIG. 6. Absence of qualitative changes in pp89 processing but an increase in pp89 peptide yield by IFN-y. (A) After a 48-h exposure with IFN-y,
BALB/c MEF were infected with MCMV under IE-plus-E conditions. At 10 h postinfection acid-soluble molecules were extracted and separated
by size exclusion chromatography, followed by reverse-phase HPLC using the indicated acetonitrile gradient for elution. HPLC fractions were tested
in triplicates with pp89-specific CTL for their content of antigenic peptides. (B) The antigenic peptides in peak fraction 27 were quantified by testing
serial dilutions in the 5"Cr-release assay. The calculated number of infected cells from which peptides were recovered is given on the horizontal axis.
The detection limit of pp89 peptides by CTL in this experiment is indicated as a dotted line. The symbols are defined as for panel A.
sequence YPHFMPTNL (9). Notably, however, the serial
dilution of the peak fraction 27 revealed a 25-fold higher
amount of the peptide in cells incubated with 20 U of IFN-y
per ml (Fig. 6B). The increase implied an enhancement of
pp89 processing to the finally trimmed peptide, or an increased
stability of the peptide, or both. Although the peptide yield was
considerably higher, the amount and stability of the antigenic
protein pp89 remained constant under conditions positive or
negative for antigen presentation (data not shown). This
observation indicates that it is not the amount of the viral
protein which represents the limiting factor during antigen
presentation.
IFN-'y induces overexpression of MHC class I molecules
without changing Ld conformation. The MHC class I heavy-
chain Ld exists in conformations that differ in terms of protein
folding, 132m association, peptide binding, and intracellular
transport (24, 40). Since 90% of all Ld molecules in MEF
belong to the 12m free-heavy-chain species, termed Ldalt (40),
we wondered whether IFN-y shifts the ratio of the Ld confor-
mations in favor of 12m-associated heavy chains. IFN-y has
been reported to induce the association of MHC class I heavy
chains with 12m in MHC class I-deficient tumor cells which
express constitutively unassembled heavy chains (19, 39).
Quantitative immunoprecipitations after [35S]methionine
pulse-labelling of IFN-y-preincubated E-phase-expressing
cells demonstrated a strong increase of 32m-assembled Ld
heavy chains (Fig. 7A, right panel), which corresponded to a
factor of 20 to 30 in cytofluorometric analysis (data not shown),
and also of Ldalt molecules (Fig. 7A, left panel). Yet, IFN-y
did not alter the ratio and the stability of the two forms either
at 180 min of chase (Fig. 7A) or at later time points (data not
shown) but led to a strong induction of both MHC class I
conformations. From these data, we conclude that the IFN-y-
dependent pp89 presentation by Ld was not due to a redistri-
bution of Ldalt heavy chains to correct assembled ternary Ld
complexes.
Establishment of MHC class I transport by IFN--y. The
failure to present pp89 peptides under conditions of E gene
expression (Fig. lG) is caused by a retention of nascent
assembled trimolecular MHC class I complexes within the
constitutive secretory pathway. This is reflected by the sus-
tained Endo H-sensitive phenotype of the N-linked carbohy-
drate moieties of the MHC class I glycoproteins (7). Since
Endo H resistance is acquired by further modifications of the
glycan structure that are catalyzed by enzymes in the medial-
Golgi apparatus (20), the blockade is located proximate to this
compartment. In order to analyze the rate of intracellular
MHC class I transport, metabolically labelled Ld molecules
were precipitated in a conformation-specific manner and sub-
jected to Endo H digestion. MCMV-infected cells express low
amounts of Ldalt molecules as well as Ld-i2m complexes (Fig.
7). Nearly all of the Ldalt, and, because of the viral transport
inhibition, also most of the Ld_P2m (Fig. 7A) as well as Dd_P2m
(Fig. 7B) complexes were still in an Endo H-susceptible state
after 180 min of chase. Conditioning of cells by IFN-y led to a
strong increase in the synthesis of Ld molecules. Associated
with the higher amount of Ld molecules was the emergence of
Endo H-resistant forms. Results of essentially the very same
type were found for Dd_P2m complexes (Fig. 7B). Note that in
spite of the increase in class I exit the majority of the
complexes were still retained in the endoplasmic reticulum-
cis-Golgi, as indicated by an Endo H-sensitive state (Fig. 7A
and B). Therefore, the majority of Endo H-sensitive class I
complexes were still retained as a result of the MCMV E gene
function.
The restoration of antigen presentation therefore comprises
two events. One is the overexpression of class I molecules,
which is associated with a higher load of antigenic peptides. In
consequence, a fraction of peptide-loaded MHC molecules
escapes the activity of the viral factor, acquires Endo H
resistance, and is transported to the cell surface to present the
peptides to CTL.
Neutralization of IFN-,y prevents the antiviral effector func-
tion of CD8+ T cells in vivo. The results described above
predict that IFN-y should act as a cofactor for CD8+ T-
lymphocyte recognition also in vivo. To address this possibility,
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FIG. 7. (A and B). IFN--y-induced overexpression of MHC class I molecules does not change the ratio of alternative Ld conformations but
restores the defective transport of MHC complexes through the medial-Golgi compartment. MCMV-infected cells were treated with CH and actD
as described in Materials and Methods. After removal of CH, cells were pulse-labelled with [35S]methionine for 90 min and then chased for 180
min. Immunoprecipitations were performed sequentially first with the MAb 64-3-7 (Ldalt; panel A, left side), then with the MAb 28-14-8S (L';
panel A, right side), and finally with the MAb 34-5-8S (Dd; panel B). Before gel electrophoresis, the +-marked samples were subjected to Endo
H digestion. The forms resulting from enzymatic cleavage are indicated on the right with S (for susceptible) or R (for resistant).
an adoptive cell transfer model was used that measures the
antiviral activity of transferred lymphocytes in MCMV-in-
fected recipients immunodepleted by 6-Gy total-body gamma-
irradiation. A previous study has demonstrated the CD4+
T-lymphocyte subset as a source of IFN-y production during
MCMV-infection in vivo (26). To exclude CD4+ T-cell-derived
IFN-y as a substitute for this CD8+ T-cell function, donor mice
were thymectomized and long-term depleted of CD4+ T cells.
As depicted in Fig. 8, MCMV-primed donor cells limited
productive virus infection in tissues which are critical in CMV
disease (33, 37), namely, the lungs and the adrenal glands. As
expected, depletion of the CD8+ T-lymphocyte subset, the
principal effector cell population in the adoptive transfer
recipients, abrogated the clearance function. Remarkably, a
similar loss of virus control resulted also from the neutraliza-
tion of IFN-y. IFN--y has a rather limited direct antiviral
activity in vivo (26) and cannot replace CD8+ effector cells
when administered in vivo (15a). These results are consistent
with the hypothesis that the IFN-y effect on antigen presenta-
tion is of relevance also in vivo.
DISCUSSION
In response to infection with MCMV, BALB/c mice gener-
ate MHC class I-restricted protective CD8+ T lymphocytes
(36). These cells can operate independently of CD4+ T cells
(33) and recognize predominantly the IE protein pp89-derived
peptide YPHFMPTNL, which is presented by the MHC class
I molecule Ld (9, 35). Analysis of pp89 presentation in vitro
revealed that viral E genes abolish presentation of defined
MCMV IE antigens including pp89 without affecting resident
MHC class I molecules at the cell surface (8). The inhibitory
mechanism is caused by an interference by E gene products
with the transport of newly assembled and peptide-loaded
MHC class I molecules through the Golgi compartment. At
later steps of infection, this results in a strong reduction of
surface-expressed class I molecules (7). Whether the later
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FIG. 8. The antiviral function of adoptively transferred CD8+ T
cells requires endogenous IFN--y. The virus clearance by 2 x 105
adoptively transferred lymphocytes from MCMV-primed, long-term
CD4+-depleted mice in individual MCMV-infected irradiated recipi-
ents was compared. Recipient mice were treated with anti-CD8 MAb
(aCD8), anti-IFN-y (oIFN-y), or rat IgG (0) as described in Materials
and Methods. Organ titers determined 2 weeks after lymphocyte
transfer from individual mice (circles) and median values (horizontal
bars) are indicated. DL, detection limit.
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effects in surface MHC expression are solely due to the block
of egress or whether the time of surface residence is also
reduced is not yet known.
In this report, we extend previous findings and provide a
rational explanation of why, despite a lack of pp89 antigen
presentation by infected cells in vitro, CD8+ cells with speci-
ficity for this antigen are nevertheless generated and have
protective properties in vivo (16, 36).
To solve this paradox, it was necessary to maintain that
either antigen presentation in certain cell types is resistant to
the viral effect, or that the degree of inhibition is subject to
regulation, or both. Here, we have studied the second alterna-
tive and report that IFN--y can rescue the antigen presentation
function from the inhibitory effect. We find that although
active at several steps of the processing and presentation
pathway, the pivotal activity of IFN--y is to mediate the export
of peptide-loaded class I molecules to the cell surface. The
major new information is that a cytokine can effectively oppose
the evasion potential of a virus.
The first alternative, that some cells may be constitutively
resistant to the viral effect, is still not excluded by these
observations. In fact, particular cell types are able to present
pp89 peptide constitutively during permissive infection in vitro
(13a). However, antigen presentation by certain cells cannot
explain all in vivo findings. Although cells resistant to the E
gene effect may suffice to initiate a vigorous CD8+ T-lympho-
cyte response, this still leaves unexplained how activated
pp89-specific T cells protect against lethal infection (16, 36) if
in vivo fibroblasts are refractory to control by these cells. To
explain the in vivo function of such CD8+ T lymphocytes, we
postulated that the blocking of antigen presentation must be
subject to regulation. We observed that incubation of fibro-
blasts in vitro with conditioned media from CD8+ T-lympho-
cyte cultures prior to MCMV infection rendered them suscep-
tible to attack by pp89-specific CTL. Hypothetically, that could
be due to many factors. However, inhibition with antibodies to
IFN-,y or usage of recombinant IFN--y shows that IFN-y can
mediate this effect on its own and that the concentration of
locally released IFN--y is sufficient to suggest that similar effects
are operative in vivo. Although we cannot exclude the activity
of other factors, this cytokine probably represents a major
contributor. Support for this conclusion includes the finding
that the antiviral CD8+ T-cell effector function in vivo requires
IFN-y.
The documented antiviral effect of pp89-specific T cells in
vivo protects against death but not against severe infection (16,
36). Since the CD8+ T-cell function is demonstrated here to be
directly dependent on IFN-y, it is not surprising that the
efficacy of this effector cell population is limited in its capacity
to control disseminating virus and to restrict MCMV spreading
to new sites of infection where cytokine levels are low.
An initial IFN-,y release is required to initiate the presenta-
tion of the viral antigen under study. Which are the probable
sources of IFN--y? If we consider CD8+ T lymphocytes as
IFN-y producers, some initial MCMV antigen presentation
must occur. This is the case because of the constitutive
resistance to the E gene effect mentioned above. In addition,
MCMV antigens that do not require the effect of IFN-y for
presentation, for instance, structural components of the virus
introduced into the cell during infection (8, 34), exist. The
initiation of a protective CD8+ T lymphocyte response can
occur in the absence of CD4+ T lymphocytes (17, 33). Never-
theless, considering the fully immunocompetent host, CD4+ T
lymphocytes and NK cells which are activated during the initial
steps of MCMV infection by MHC class I-independent mech-
anisms are also likely to represent major sources of IFN--y (5,
26).
IFN-y-treated and subsequently infected cells contain about
25-fold more naturally processed peptide than untreated cells,
yielding approximately 105 extractable peptides per cell, which
is a significantly higher number than estimates for in vitro
virus-infected cells (38). This shows that peptide presentation
in vitro and in vivo can differ considerably in quantity. How
IFN--y affects processing and peptide transport is at present
poorly defined. We focused on MHC class I molecule biosyn-
thesis and transport because it is generally held that the
half-life of peptides is short unless complex formation with
MHC class I molecules occurs. Therefore, any effect on
processing and endoplasmic reticulum transport of peptides
only, without affecting MHC class I molecule export, would not
have rescued antigen presentation. As far as can be judged by
the methods used, the observed increase in MHC class I
expression is in good agreement with the increase in the
amount of peptides.
We have previously shown that presence of processed viral
peptides in cells is not necessarily associated with antigen
presentation (7). Because IFN-y rescues presentation, two
possibilities existed: either a cessation of the viral effect by
interference with the negative factor or an escape from the
inhibition by a surplus of peptide-loaded molecules. Although
an action of IFN--y on the viral protein cannot be excluded,
because the responsible E phase protein is not yet defined, the
data provided the answer that the latter alternative is probably
correct. IFN--y-treated cells synthesize much greater numbers
of class I molecules, and only in these cells is there also
sufficient export to the cell surface. Although many molecules
were now transported to the cell surface, the viral factor was
nevertheless able to retain a major fraction of complexes.
Viruses have evolved different strategies to evade or coun-
teract immune control, such as expression of cytokines, cyto-
kine receptors, or production of enzymes that regulate cyto-
kine function and thus interfere with their function (for a
review, see reference 13). This is the first example in which a
cytokine can compensate the evasion potential of a virus. The
observation that preincubation of at least 12 h is required to
override the viral inhibition does not argue against this role of
the cytokine in vivo. The replication cycle of MCMV is slow
and takes about 24 h; the replication cycle of human CMV
(HCMV) is even more protracted. Thus, if the situation found
for the MCMV model also applies for HCMV, cytokines
released during a first round of replication could already
provide antigen presentation and cause recognition of neigh-
boring cells that are infected during a second round. It is clear,
however, that during immunodeficiency, when IFN--y release is
low or absent, antigen presentation would remain poor. This
view is supported by the finding that neutralization of IFN--y
can abrogate the function of adoptively transferred antiviral
CD8+ T cells in immunocompromised recipient mice at least
in tissues that are critical in MCMV disease, e.g., lungs or
adrenal glands. We make the tacit assumption that these
mechanisms, like so many others of the MCMV model, also
apply to HCMV infection. This would explain the well-known
disposition of immunocompromised individuals with deficient
IFN--y responses, like AIDS patients (28), to CMV disease (11,
14). Although the HCMV effect on antigen presentation has
not been studied, a negative effect has been discussed because
HCMV also has a negative effect on MHC class I surface
expression (1). On the molecular level, the mechanisms by
which HCMV interferes with MHC class I molecules appear
different from those of MCMV (2, 3, 7), but it will now be of
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interest to see whether IFN-y has an enhancing effect on MHC
class I complex formation in HCMV-infected cells.
ACKNOWLEDGMENTS
We thank T. Hansen for hybridomas secreting MAb directed against
Ld and Matthias J. Reddehase and Margarita del Val for helpful
discussion. The skillful technical assistance of Brigitte Reutter and
Jutta Spath and the preparation of the manuscript by I. Bennett are
greatly appreciated.
This work was supported by the Deutsche Forschungsgemeinschaft
(Ko 571 and SFB 322) and the Ministerium fur Wirtschaft und
Forschung Baden-Wurttemberg (7532.292-1).
REFERENCES
1. Barnes, P., and J. E. Grundy. 1992. Down-regulation of the class
I HLA heterodimer and P2-microglobulin on the surface of cells
infected with cytomegalovirus. J. Gen. Virol. 73:2395-2403.
2. Browne, H., M. Churcher, and T. Minson. 1992. Construction and
characterization of a human cytomegalovirus mutant with the
UL18 (class I homolog) gene deleted. J. Virol. 66:6784-6787.
3. Browne, H., G. Smith, S. Beck, and T. Minson. 1990. A complex
between the MHC class I homologue encoded by human cytomeg-
alovirus and 13 microglobulin. Nature (London) 347:770-772.
4. Bubler, B., G. M. Keil, F. Weiland, and U. H. Koszinowski. 1990.
Characterization of the murine cytomegalovirus early transcrip-
tion unit el that is induced by immediate-early proteins. J. Virol.
64:1907-1919.
5. Bukowski, J., J. F. Warner, G. Dennert, and R. M. Welsh. 1985.
Adoptive transfer studies demonstrating the antiviral effect of
natural killer cells in vivo. J. Exp. Med. 161:40-52.
6. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, and H.
Waldmann. 1984. Therapy with monoclonal antibodies by elimi-
nation of T-cell subsets in vivo. Nature (London) 328:548-550.
7. Del Val, M., H. Hengel, H. Hacker, U. Hartlaub, T. Ruppert, P.
Lucn, and U. H. Koszinowski. 1992. Cytomegalovirus prevents
antigen presentation blocking the transport of peptide-loaded
major histocompatibility complex class I molecules into the medi-
al-Golgi compartment. J. Exp. Med. 172:729-738.
8. Del Val, M., K. Munch, M. J. Reddehase, and U. H. Koszinowski.
1989. Presentation of cytomegalovirus immediate-early antigens to
cytolytic T lymphocytes is selectively blocked by viral genes
expressed in the early phase. Cell 58:305-315.
9. Del Val, M., H.-J. Schlicht, T. Ruppert, M. J. Reddehase, and
U. H. Koszinowski. 1991. Efficient processing of an antigenic
sequence for presentation by MHC class I molecules depends on
its neighboring residues in the protein. Cell 66:1145-1153.
10. Del Val, M., H. Volkmer, J. B. Rothbard, S. Jonjic, M. Messerle,
J. Schickedanz, M. J. Reddehase, and U. H. Koszinowski. 1988.
Molecular basis for cytolytic T-lymphocyte recognition of the
murine cytomegalovirus immediate early protein pp89. J. Virol.
62:3965-3972.
11. Drew, W. L., and L. Mintz. 1984. Cytomegalovirus infection in
healthy and immune-deficient homosexual men, p. 117-123. In P.
Ma and D. Armstrong (ed.), The acquired immune deficiency
syndrome and infections of homosexual men. Yorke Medical
Books, New York.
12. Echtenacher, B., W. Falk, D. N. Mannel, and P. H. Krammer.
1990. Requirement of endogenous tumor necrosis factor/cachectin
for recovery from experimental peritonitis. J. Immunol. 145:3762-
3768.
13. Gooding, L. R. 1992. Virus proteins that counteract host immune
defense. Cell 71:5.
13a.Hengel, H. Unpublished data.
14. Ho, M. 1982. Human cytomegalovirus infections in immunosup-
pressed patients, p. 171-204. In W. B. Greenough and T. C.
Merrigan (ed.), Cytomegalovirus, biology and infection: current
topics in infectious disease. Plenum Press, New York.
15. Hsu, V. W., L. C. Yuan, J. G. Nuchtern, J. Lippincott-Schwartz,
G. J. Hammerling, and R. D. Klausner. 1991. A recycling pathway
between the endoplasmic reticulum and the Golgi apparatus for
retention of unassembled MHC class I molecules. Nature (Lon-
don) 352:441-444.
15a.Jonjic, S. Unpublished data.
16. Jonjic, S., M. Del Val, G. M. Keil, M. J. Reddehase, and U. H.
Koszinowski. 1988. A nonstructural viral protein expressed by a
recombinant vaccinia virus protects against lethal cytomegalovirus
infection. J. Virol. 62:1653-1658.
17. Jonjic, S., W. Mutter, F. Weiland, M. J. Reddehase, and U. H.
Koszinowski. 1989. Site-restricted persistent cytomegalovirus in-
fection after selective long-term depletion of CD4+ T lympho-
cytes. J. Exp. Med. 169:1199-1212.
18. Kelly, A., S. H. Powis, R. Glynne, E. Radley, S. Beck, and J.
Trowsdale. 1991. Second proteasome-related gene in the human
MHC class II region. Nature (London) 353:667-668.
19. Klar, D., and G. J. Hammerling. 1989. Induction of assembly of
MHC class I heavy chains with 12 microglobulin by interferon-Y.
EMBO J. 8:475-481.
20. Kornfeld, R., and S. Kornfeld. 1985. Assembly of asparagine-
linked oligosaccharides. Annu. Rev. Biochem. 54:631-664.
21. Koszinowski, U. H., M. Del Val, and M. J. Reddehase. 1990.
Cellular and molecular basis of the protective immune response to
cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 154:
189-220.
22. Kvist, S., and U. Hamann. 1990. A nucleoprotein peptide of
influenza A virus stimulates assembly of HLA-B27 class I heavy
chains and 12-microglobulin translated in vitro. 1990. Nature
(London) 348:446-448.
23. Levy, F., R. Gabathuler, R. Larsson, and S. Kvist. 1991. ATP is
required for in vitro assembly of MHC class I antigens but not for
transfer of peptides across the ER membrane. Cell 67:265-274.
24. Lie, W.-R., N. B. Myers, J. M. Connolly, J. Gorka, D. R. Lee, and
T. H. Hansen. 1991. The specific binding of peptide ligand to Ld
class I major histocompatibility complex molecules determines
their antigenic structure. J. Exp. Med. 173:449-459.
25. Lie, W.-R., N. B. Myers, J. Gorka, R. J. Rubocki, J. M. Connolly,
and T. H. Hansen. 1990. Peptide ligand induced conformation and
surface expression of the Ld class I MHC molecule. Nature
(London) 344:439-441.
26. Lucn, P., I. Pavic, B. Polic, S. Jonjic, and U. H. Koszinowski. 1992.
Gamma interferon-dependent clearance of cytomegalovirus infec-
tion in salivary glands. J. Virol. 66:1977-1984.
27. Martinez, C. K., and J. J. Monaco. 1991. Homology of proteasome
subunits to a major histocompatibility complex-linked LMP gene.
Nature (London) 353:664-667.
28. Murray, H., B. Rubin, H. Masur, and R. B. Roberts. 1984.
Impaired production of lymphokines and immune (gamma) inter-
feron in the acquired immunedeficiency syndrome. N. Engl. J.
Med. 310:883-888.
29. Ortiz-Navarrete, V., A. Seelig, M. Gernold, S. Frentzel, P. M.
Kloetzel, and G. J. Hammerling. 1991. Subunit of the 20s protea-
some (multicatalytic proteinase) encoded by the major histocom-
patibility complex. Nature (London) 353:662-664.
30. Pestka, S., J. A. Langer, K. C. Zoon, and C. E. Samuel. 1987.
Interferons and their actions. Annu. Rev. Biochem. 56:727-777.
31. Powis, S., A. R. M. Townsend, E. V. Deverson, J. Bastin, G. W.
Butcher, and J. C. Howard. 1991. Restoration of antigen presen-
tation to the mutant cell line RMA-S by an MHC-linked trans-
porter. Nature (London) 354:528-531.
32. Prat, M., G. Gribaudo, P. M. Comoglio, G. Cavallo, and S.
Landolfo. 1984. Monoclonal antibodies against murine -y inter-
feron. Proc. Natl. Acad. Sci. USA 81:4515-4519.
33. Reddehase, M. J., S. Jonjic, F. Weiland, W. Mutter, and U. H.
Koszinowski. 1988. Adoptive immunotherapy of murine cytomeg-
alovirus adrenalitis in the immunocompromised host: CD4-helper-
independent antiviral function of CD8-positive memory T lympho-
cytes derived from latently infected donors. J. Virol. 62:1061-1065.
34. Reddehase, M. J., G. M. Keil, and U. H. Koszinowski. 1984. The
cytolytic T lymphocyte response to the murine cytomegalovirus II.
Detection of virus replication stage-specific antigens by separate
populations of in vivo active cytolytic T lymphocyte precursors.
Eur. J. Immunol. 14:56-61.
35. Reddehase, M. J., and U. H. Koszinowski. 1984. Significance of
herpesvirus immediate early gene expression in cellular immunity
to cytomegalovirus infection. Nature (London) 312:369-371.
36. Reddehase, M. J., W. Mutter, K. Munch, H.-J. Buhring, and U. H.
J. VIROL.
 at Universitaetsbibliothek M
uenchen on O
ctober 22, 2008 
jvi.asm.org
D
ow
nloaded from
 
IFN--y RESTORES DEFECTIVE ANTIGEN PRESENTATION 297
Koszinowski. 1987. CD8-positive T lymphocytes specific for mu-
rine cytomegalovirus immediate-early antigens mediate protective
immunity. J. Virol. 61:3102-3108.
37. Reddehase, M. J., F. Weiland, K. Munch, S. Jonjic, A. Luske, and
U. H. Koszinowski. 1985. Interstitial murine cytomegalovirus
pneumonia after irradiation: characterization of cells that limit
viral replication during established infection of the lungs. J. Virol.
55:264-273.
38. Rotzschke, O., K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger,
G. Jung, and H.-G. Rammensee. 1990. Isolation and analysis of
naturally processed viral peptides as recognized by cytotoxic T
cells. Nature (London) 348:252-254.
39. Sibille, C., K. Gould, G. Hammerling, and A. Townsend. 1992. A
defect in the presentation of intracellular viral antigens is restored
by interferon-y in cell lines with impaired major histocompatibility
complex class I assembly. Eur. J. Immunol. 22:433-440.
40. Smith, J. D., W.-R. Lie, J. Gorka, C. S. Kindle, N. B. Myers, and
T. H. Hansen. 1992. Disparate interaction of peptide ligand with
nascent versus mature class I major histocompatibility complex
molecules: comparisons of peptide binding to alternative forms of
Ld in cell lysates and the cell surface. J. Exp. Med. 175:191-202.
41. Spies, T., M. Bresnahon, S. Bahram, D. Arnold, G. Blanck, E.
Mellus, D. Pious, and R. DeMars. 1990. A gene in the human
major histocompatibility complex class II region controlling the
class I antigen presentation pathway. Nature (London) 348:744-
747.
42. Townsend, A., and H. Bodmer. 1989. Antigen recognition by class
I-restricted T lymphocytes. Annu. Rev. Immunol. 7:601-624.
43. Townsend, A., T. Elliott, V. Cerundolo, L. Foster, B. Barber, and
A. Tse. 1990. Assembly ofMHC class I molecules analyzed in vitro.
Cell 62:285-295.
44. Wong, G. H. W., I. Clark-Lewis, J. L. McKimm-Breschkin, A. W.
Harris, and J. W. Schrader. 1983. Interferon-y induces enhanced
expression of Ia and H-2 antigens on B lymphoid, macrophage,
and myeloid cell lines. J. Immunol. 131:788-793.
VOL. 68, 1994
 at Universitaetsbibliothek M
uenchen on O
ctober 22, 2008 
jvi.asm.org
D
ow
nloaded from
 
